Never miss an issue of Master Investor Magazine – sign-up now for free!
AstraZeneca’s (LON:AZN) share price rose by 2.25% to 5,989p (as of 14:15 GMT) after product sales in the third quarter climbed by 8% on the back of new products and emerging markets.
Pascal Soriot, the chief executive at the FTSE 100 pharmaceutical giant, commented: “Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come. Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in Emerging Markets.
These new medicines are showing great promise, including Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma. We’re also continuing to replenish our early-stage pipeline as we bring our innovative medicines to patients around the world“.